secwatch.observer — SEC 8-K summary
======================================

Issuer:     GeoVax Labs, Inc. (GOVX)
CIK:        0000832489
Form:       8-K
Filed at:   2025-05-01T23:59:59+00:00
Accession:  0001437749-25-014147
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GeoVax Q1 net loss narrows to $5.4M; BARDA award ended, COVID vaccine data due Q2 2025
--------------------------------------------------------------------------------

- Net loss $5.4M (vs $5.9M Q1 2024); revenue $1.6M from BARDA contract (none prior year).
- Cash $7.4M at Mar 31, 2025, up from $5.5M at Dec 31, 2024.
- BARDA Project NextGen award terminated unexpectedly; GEO-CM04S1 COVID vaccine continues.
- Healthy adult booster data for GEO-CM04S1 expected Q2 2025; GEO-MVA trial starts H2 2025.
- Gedeptin advancing to Phase 2 for recurrent head/neck cancer with checkpoint inhibitor.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/832489/000143774925014147/0001437749-25-014147-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/832489/000143774925014147/govx20250430_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-014147

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer